Table 3.
Baseline Characteristics of Statin‐Exposed and Unexposed Women in the Anthracycline and Trastuzumab Cohorts After Propensity Score Matching
| Variable | Anthracycline Cohort | Trastuzumab Cohort | ||||
|---|---|---|---|---|---|---|
| Unexposed | Exposed | Std Diff | Unexposed | Exposed | Std Diff | |
| No. | 666 | 666 | … | 390 | 390 | … |
| Median age, y (IQR) | 69 (67–72) | 69 (67–73) | 0.02 | 71 (68–75) | 71 (68–75) | <0.01 |
| Cohort entry, y | ||||||
| 2007, n (%) | 60 (9.0%) | 49 (7.4%) | 0.06 | 23 (5.9%) | 16 (4.1%) | 0.08 |
| 2008, n (%) | 48 (7.2%) | 44 (6.6%) | 0.02 | 25 (6.4%) | 18 (4.6%) | 0.08 |
| 2009, n (%) | 49 (7.4%) | 50 (7.5%) | 0.01 | 20 (5.1%) | 28 (7.2%) | 0.09 |
| 2010, n (%) | 48 (7.2%) | 52 (7.8%) | 0.02 | 19 (4.9%) | 31 (7.9%) | 0.13 |
| 2011, n (%) | 49 (7.4%) | 63 (9.5%) | 0.08 | 29 (7.4%) | 28 (7.2%) | 0.01 |
| 2012, n (%) | 61 (9.2%) | 43 (6.5%) | 0.1 | 31 (7.9%) | 30 (7.7%) | 0.01 |
| 2013, n (%) | 68 (10.2%) | 71 (10.7%) | 0.01 | 45 (11.5%) | 44 (11.3%) | 0.01 |
| 2014, n (%) | 67 (10.1%) | 65 (9.8%) | 0.01 | 48 (12.3%) | 45 (11.5%) | 0.02 |
| 2015, n (%) | 70 (10.5%) | 70 (10.5%) | <0.01 | 46 (11.8%) | 48 (12.3%) | 0.02 |
| 2016, n (%) | 80 (12.0%) | 75 (11.3%) | 0.02 | 48 (12.3%) | 50 (12.8%) | 0.02 |
| 2017, n (%) | 66 (9.9%) | 84 (12.6%) | 0.09 | 56 (14.4%) | 52 (13.3%) | 0.03 |
| Nearest census based neighbourhood income quintile | ||||||
| 1, n (%) | 127 (19.1%) | 123 (18.5%) | 0.02 | 73 (18.7%) | 72 (18.5%) | 0.01 |
| 2, n (%) | 141 (21.2%) | 135 (20.3%) | 0.02 | 83 (21.3%) | 88 (22.6%) | 0.03 |
| 3, n (%) | 132 (19.8%) | 140 (21.0%) | 0.03 | 88 (22.6%) | 88 (22.6%) | <0.01 |
| 4, n (%) | 149 (22.4%) | 145 (21.8%) | 0.01 | 63 (16.2%) | 69 (17.7%) | 0.04 |
| 5, n (%) | 116 (17.4%) | 122 (18.3%) | 0.02 | 83 (21.3%) | 72 (18.5%) | 0.07 |
| Rural residence, n (%) | 92 (13.8%) | 91 (13.7%) | <0.01 | 52 (13.3%) | 54 (13.8%) | 0.01 |
| Prior anthracycline, n (%) | … | … | … | 166 (42.6%) | 166 (42.6%) | <0.01 |
| Breast cancer stage | ||||||
| 1, n (%) | 111 (16.7%) | 109 (16.4%) | 0.01 | 127 (32.6%) | 121 (31.0%) | |
| 2, n (%) | 339 (50.9%) | 345 (51.8%) | 0.02 | 178 (45.6%) | 190 (48.7%) | |
| 3, n (%) | 216 (32.4%) | 212 (31.8%) | 0.01 | 85 (21.8%) | 79 (20.3%) | |
| Left‐sided disease*, n (%) | 359 (53.9%) | 360 (54.1%) | <0.01 | 210 (53.8%) | 212 (54.4%) | 0.01 |
| Charlson index, median (IQR) | 0 (0–6) | 1 (0–6) | 0.08 | 0 (0–6) | 0 (0–6) | 0.04 |
| Myocardial infarction, n (%) | <6 | <6 | <0.01 | <6 | <6 | 0.06 |
| Ischemic heart disease without myocardial infarction, n (%) | 44 (6.6%) | 54 (8.1%) | 0.06 | 29 (7.4%) | 31 (7.9%) | 0.02 |
| Peripheral vascular disease, n (%) | <6 | <6 | <0.01 | <6 | <6 | 0.08 |
| Atrial fibrillation, n (%) | 25 (3.8%) | 28 (4.2%) | 0.02 | 17 (4.4%) | 17 (4.4%) | <0.01 |
| Diabetes mellitus, n (%) | 153 (23.0%) | 155 (23.3%) | 0.01 | 94 (24.1%) | 100 (25.6%) | 0.04 |
| Hypertension, n (%) | 530 (79.6%) | 507 (76.1%) | 0.08 | 316 (81.0%) | 305 (78.2%) | 0.07 |
| Chronic kidney disease, n (%) | 18 (2.7%) | 18 (2.7%) | <0.01 | 13 (3.3%) | 14 (3.6%) | 0.01 |
| Chronic obstructive pulmonary disease, n (%) | 112 (16.8%) | 114 (17.1%) | 0.01 | 69 (17.7%) | 65 (16.7%) | 0.03 |
| Angiotensin antagonists, n (%) | 361 (54.2%) | 363 (54.5%) | 0.01 | 222 (56.9%) | 220 (56.4%) | 0.01 |
| Beta blockers, n (%) | 144 (21.6%) | 136 (20.4%) | 0.03 | 87 (22.3%) | 86 (22.1%) | 0.01 |
| Non‐statin lipid‐lowering drugs, n (%) | 34 (5.1%) | 33 (5.0%) | 0.01 | 19 (4.9%) | 24 (6.2%) | 0.06 |
| LDL level at baseline | ||||||
| Missing, n (%) | 374 (56.2%) | 283 (42.5%) | 0.28 | 219 (56.2%) | 157 (40.3%) | 0.32 |
| <2.0, n (%) | 20 (3.0%) | 162 (24.3%) | 0.65 | 16 (4.1%) | 108 (27.7%) | 0.68 |
| 2.0–3.49, n (%) | 191 (28.7%) | 193 (29.0%) | 0.01 | 113 (29.0%) | 114 (29.2%) | 0.01 |
| 3.5–5.0, n (%) | 76–80 | 28 (4.2%) | 0.28 | 37–41 | 6–10 | 0.33 |
| >5.0, n (%) | <6 | 0 | 0.1 | <6 | <6 | <0.01 |
In accordance with ICES privacy policies, cells with <6 counts are suppressed. LDL indicates low‐density lipoprotein; IQR, interquartile range; and Std diff indicates standardized difference.
Breast cancer laterality data missing for 7 anthracycline‐treated and <6 trastuzumab‐treated women.